Comparison of Intravenous Immunoglobulins for Naturally Occurring Autoantibodies against Amyloid-β

被引：20

作者：

Balakrishnan, Karthikeyan ^{[1
]}

Andrei-Selmer, Luminita-Cornelia ^{[1
,2
]}

Selmer, Thorsten ^{[3
,4
]}

Bacher, Michael ^{[1
]}

Dodel, Richard ^{[1
]}

机构：

[1] Univ Marburg, Dept Neurol, D-35039 Marburg, Germany

[2] Univ Bonn, Dept Neuroanat, D-5300 Bonn, Germany

[3] Univ Marburg, Dept Microbiol, D-35039 Marburg, Germany

[4] Aachen Univ Appl Sci, Dept Chem & Biotechnol, Julich, Germany

来源：

JOURNAL OF ALZHEIMERS DISEASE | 2010年 / 20卷 / 01期

关键词：

Alzheimer's disease; amyloid-beta specific nAbs; immunotherapy for AD; IVIG; ALZHEIMERS-DISEASE; ANTIBODIES; PEPTIDE; IGIV;

D O I：

10.3233/JAD-2010-1353

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Intravenous immunoglobulins (IVIG) are currently used for therapeutic purposes in autoimmune disorders. Recently, we demonstrated the presence of naturally occurring antibodies against amyloid-beta (nAbs-A beta) within the pool of IVIG. In this study, we compared different brands of IVIG for nAbs-A beta and have found differences in the specificity of the nAbs-A beta towards A beta(1-40) and A beta(1-42). We analyzed the influence of a pH-shift over the course of antibody storage using ELISA and investigated antibody dimerization at acidic and neutral pH as well as differences in the IgG subclass distributions among the IVIG using both HPLC and a nephelometric assay. Furthermore, we investigated the epitope region of purified nAbs-A beta. The differences found in A beta specificity are not directly proportionate to the binding nature of these antibodies when administered in vivo. This information, however, may serve as a guide when choosing the commercial source of IVIG for therapeutic applications in Alzheimer's disease.

引用

页码：135 / 143

页数：9

共 23 条

[1] Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease [J].

Britschgi, M. ;

Olin, C. E. ;

Johns, H. T. ;

Takeda-Uchimura, Y. ;

LeMieux, M. C. ;

Rufibach, K. ;

Rajadas, J. ;

Zhang, H. ;

Tomooka, B. ;

Robinson, W. H. ;

Clark, C. M. ;

Fagan, A. M. ;

Galasko, D. R. ;

Holtzman, D. M. ;

Jutel, M. ;

Kaye, J. A. ;

Lemere, C. A. ;

Leszek, J. ;

Li, G. ;

Peskind, E. R. ;

Quinn, J. F. ;

Yesavage, J. A. ;

Ghiso, J. A. ;

Wyss-Coray, T. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (29) :12145-12150

[2] Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease [J].

DeMattos, RB ;

Bales, KR ;

Cummins, DJ ;

Dodart, JC ;

Paul, SM ;

Holtzman, DM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (15) :8850-8855

[3] Human antibodies against amyloid β peptide:: A potential treatment for Alzheimer's disease [J].

Dodel, R ;

Hampel, H ;

Depboylu, C ;

Lin, SZ ;

Gao, F ;

Shock, S ;

Jäckel, S ;

Wei, W ;

Buerger, K ;

Höft, C ;

Hemmer, B ;

Möller, HJ ;

Farlow, M ;

Oertel, WH ;

Sommer, N ;

Du, YS .

ANNALS OF NEUROLOGY, 2002, 52 (02) :253-256

[4]

DODEL R, 2009, CNS DRUGS IN PRESS

[5] Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer's disease [J].

Dodel, RC ;

Du, Y ;

Depboylu, C ;

Hampel, H ;

Frölich, L ;

Haag, A ;

Hemmeter, U ;

Paulsen, S ;

Teipel, SJ ;

Brettschneider, S ;

Spottke, A ;

Nölker, C ;

Möller, HJ ;

Wei, X ;

Farlow, M ;

Sommer, N ;

Oertel, WH .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (10) :1472-1474

[6] Reduced levels of amyloid β-peptide antibody in Alzheimer disease [J].

Du, Y ;

Dodel, R ;

Hampel, H ;

Buerger, K ;

Lin, S ;

Eastwood, B ;

Bales, K ;

Gao, F ;

Moeller, HJ ;

Oertel, W ;

Farlow, M ;

Paul, S .

NEUROLOGY, 2001, 57 (05) :801-805

[7] Human anti-β-amyloid antibodies block β-amyloid fibril formation and prevent β-amyloid-induced neurotoxicity [J].

Du, YS ;

Wei, X ;

Dodel, R ;

Sommer, N ;

Hampel, H ;

Gao, F ;

Ma, ZZ ;

Zhao, LM ;

Oertel, WH ;

Farlow, M .

BRAIN, 2003, 126 :1935-1939

[8] Differences between IGIV products: Impact on clinical outcome [J].

Gelfand, EW .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2006, 6 (04) :592-599

[9] The ubiquitin-proteasome system postsynaptically regulates glutamatergic synaptic function [J].

Haas, Kevin F. ;

Miller, Stephanie L. H. ;

Friedman, David B. ;

Broadie, Kendal .

MOLECULAR AND CELLULAR NEUROSCIENCE, 2007, 35 (01) :64-75

[10] Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease [J].

Hock, C ;

Konietzko, U ;

Streffer, JR ;

Tracy, J ;

Signorell, A ;

Müller-Tillmanns, B ;

Lemke, U ;

Henke, K ;

Moritz, E ;

Garcia, E ;

Wollmer, MA ;

Umbricht, D ;

de Quervain, DJF ;

Hofmann, M ;

Maddalena, A ;

Papassotiropoulos, A ;

Nitsch, RM .

NEURON, 2003, 38 (04) :547-554

← 1 2 3 →